Trillium Therapeutics Inc 's ROA from the third quarter of 2021 to the third quarter of 2020 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Trillium Therapeutics Inc 's ROA in the third quarter of 2021?
Trillium Therapeutics Inc recorded a cumulative net loss of $-34 million during 12 months ending in the third quarter of 2021, resulting in a negative return on assets (ROA) of -16%.

However, within the Healthcare sector 606 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2021 quarter, so far to 4231, from total ROA ranking in the second quarter of 2021 at 4350.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2021) III. Quarter	(Jun 30 2021) II. Quarter	(Mar 31 2021) I. Quarter	(Dec 31 2020) IV. Quarter	(Sep 30 2020) III. Quarter
Y / Y Total Assets Change	26.81 %	614.14 %	1002.08 %	1031.85 %	80.56 %
Y / Y Net Income Change	-	-	-33.35 %	-	-
Net Income (TTM) in million	-34	-27	-32	-27	22
Return On Assets (TTM)	-16 %	-13.16 %	-19.05 %	-25.4 %	55.78 %
TRIL's Total Ranking	# 4231	# 4350	# 4462	# 5125	# 61
Total Assets (TTM) in million	105	181	280	288	83
Seq. Total Assets Change	-42.04 %	-35.2 %	-2.63 %	246.77 %	226.4 %
Seq. Net Income Change	-	-	-	-	-

TRIL's 5 Years Annual ROA >> Back to TRIL Management Effectiveness >> Compare TRIL ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 264
Sector	# 607
Overall	# 4115

Return On Assets Statistics
High	Average	Low
162.25 %	15.63 %	-100.64 %
(Dec 31 2019)		(Dec 31 2020)

Financial Statements
Trillium Therapeutics Inc 's Assets	$ 105 million	TRIL's Balance sheet
Trillium Therapeutics Inc 's Income	$ -19 million	Quarterly TRIL's Income Statement
TRIL's Income by Division		See TRIL's Income by Division

Annual Return On Assets	(Dec 31 2020) FY 2020	(Dec 31 2019) FY 2019	(Dec 31 2018) FY 2018	(Dec 31 2017) FY 2017	FY
Y / Y Total Assets Change	258.95 %	121.85 %	-63.44 %	-	-
Total Assets in million	366	102	46	126	0
Y / Y Net Income Change	55.84 %	-	-	-	-
Net Income in million	59	38	-33	45	0
Annual Return On Assets	16.23 %	37.37 %	-71.56 %	35.89 %	-

TRIL's 5 Years Annual ROA >> Back to TRIL Management Effectiveness >> Compare TRIL ROA to its Competitors

Comment on TRIL's ROA in the fiscal year ending 2020

In the fiscal year 2020 ROA deteriorated to 16.23 %, despite annual net income growth of 55.84 % to $59.35 million, from $38.08 million a year ago, as TRIL's assets increase to $365.75 million, by 55.84 %.

More Return On Assets Ratios
TRIL's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
TRIL's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for TRIL's Competitors
Subscribers only: Roa for Trillium Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for TRIL's Customers

You may also want to know
TRIL's Roi	TRIL's Inventory Turnover Ratio	TRIL's Growth Rates	TRIL's Dividend Comparisons
	TRIL's Profitability Ratios	TRIL's Asset Turnover Ratio	TRIL's Dividend Growth
TRIL's Roe	TRIL's Valuation Ratios	TRIL's Financial Strength Ratios	TRIL's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2021, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:33:43+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.